Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway
- PMID: 34032975
- DOI: 10.1007/s11033-021-06326-9
Fluvastatin attenuated ischemia/reperfusion-induced autophagy and apoptosis in cardiomyocytes through down-regulation HMGB1/TLR4 signaling pathway
Abstract
Fluvastatin, a traditional fat-decreasing drug, is widely used for curing cardiovascular disease. Previous reports demonstrated that fluvastatin pretreatment protected against myocardial ischemia/reperfusion (I/R) by inhibiting TLR4 signaling pathway and/or reducing proinflammatory cytokines. However, whether fluvastatin has a cardioprotective effect against apoptosis and autophagy remains unknown. This study aims to evaluate whether the cardioprotective role of fluvastatin in I/R is mediated by high-mobility group box 1 (HMGB1)/toll-like receptor 4 (TLR4) pathway via anti-apoptotic and anti-autophagic functions. Sprague-Dawley rats were anesthetized, artificially ventilated and subjected to 30 min of coronary occlusion, followed by 4 h of reperfusion. The animals were randomized into four groups: (i) Sham operation; (ii) I/R; (iii) I/R + low-dosage fluvastatin (10 mg/kg); and (iv) I/R + high-dosage fluvastatin (20 mg/kg). After reperfusion, the hemodynamic parameters, myocardial infarct size, structural alteration of myocardium, apoptosis index, pro-inflammatory cytokine production, Beclin-1, Light chain 3 (LC3), HMGB1, TLR4 and Nuclear factor kappa B (NF-κB) protein levels were measured and recorded. It was found that fluvastatin preconditioning improved left ventricular dysfunction, reduced HMGB1/TLR4/NF-κB expressions, and inhibited cardiomyocyte apoptosis, autophagy, and inflammation reaction. Moreover, treatment with fluvastatin ameliorated myocardial injury by reducing infarct size, causing less damage to cardiac structure, downregulating autophagy-related protein expression and releasing pro-inflammation mediators. Our findings indicate that fluvastatin exerts beneficial effects on cardiac ischemic damage, which may be associated with its anti-autophagic and anti-apoptotic functions via inhibition of HMGB1/TLR4-related pathway during I/R injury.
Keywords: Apoptosis; Autophagy; Cardioprotection; Fluvastatin; HMGB1/TLR4 signaling pathway; Inflammation response; Reperfusion injury.
Similar articles
-
The HMGB1-TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis.Gene. 2013 Sep 15;527(1):389-93. doi: 10.1016/j.gene.2013.05.041. Epub 2013 May 30. Gene. 2013. PMID: 23727604
-
The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4.Mol Biol Rep. 2011 Jun;38(5):3037-44. doi: 10.1007/s11033-010-9970-z. Epub 2010 Feb 4. Mol Biol Rep. 2011. PMID: 20127518
-
Dexmedetomidine Preconditioning Ameliorates Inflammation and Blood-Spinal Cord Barrier Damage After Spinal Cord Ischemia-Reperfusion Injury by Down-Regulation High Mobility Group Box 1-Toll-Like Receptor 4-Nuclear Factor κB Signaling Pathway.Spine (Phila Pa 1976). 2019 Jan 15;44(2):E74-E81. doi: 10.1097/BRS.0000000000002772. Spine (Phila Pa 1976). 2019. PMID: 29975331
-
Angiotensin 1-7 increases cardiac tolerance to ischemia/reperfusion and mitigates adverse remodeling of the heart-The signaling mechanism.Fundam Clin Pharmacol. 2024 Jun;38(3):489-501. doi: 10.1111/fcp.12983. Epub 2024 Feb 4. Fundam Clin Pharmacol. 2024. PMID: 38311344 Review.
-
The Role of NF-κB in Myocardial Ischemia/Reperfusion Injury.Curr Protein Pept Sci. 2022;23(8):535-547. doi: 10.2174/1389203723666220817085941. Curr Protein Pept Sci. 2022. PMID: 35980051 Review.
Cited by
-
Epigallocatechin-3-gallate protects cardiomyocytes from hypoxia-reoxygenation damage via raising autophagy related 4C expression.Bioengineered. 2021 Dec;12(2):9496-9506. doi: 10.1080/21655979.2021.1996018. Bioengineered. 2021. PMID: 34699312 Free PMC article.
-
Targeting high-mobility-group-box-1-mediated inflammation: a promising therapeutic approach for myocardial infarction.Inflammopharmacology. 2025 Feb;33(2):767-784. doi: 10.1007/s10787-024-01586-w. Epub 2024 Nov 2. Inflammopharmacology. 2025. PMID: 39487941 Review.
References
-
- Hillis LD, Lange RA (2006) Myocardial infarction and the open-artery hypothesis. N Engl J Med 355:2475–2477 - DOI
-
- Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, Gore JM, Weaver WD, Rogers WJ, Tiefenbrunn AJ (2000) Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 283:2941–2947 - DOI
-
- Ribichini F, Wijns W (2002) Acute myocardial infarction: reperfusion treatment. Heart 88:298–305 - DOI
-
- Liao YH, Xia N, Zhou SF, Tang TT, Yan XX, Lv BJ, Nie SF, Wang J, Iwakura Y, Xiao H, Yuan J, Jevallee H, Weig F, Shi GP, Cheng X (2012) Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J Am Coll Cardiol 59:420–429 - DOI
-
- Zhang D, He Y, Ye X, Cai Y, Xu J, Zhang L, Li M, Liu H, Wang S, Xia Z (2020) Activation of autophagy inhibits NLRP3 inflammasome activation and attenuates myocardial ischemia–reperfusion injury in diabetic rats. J Diabetes Investig https://doi.org/10.1111/jdi.13235 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources